Igarashi et al., 2018 - Google Patents
Linagliptin prevents atrial electrical and structural remodeling in a canine model of atrial fibrillationIgarashi et al., 2018
- Document ID
- 8023168160981352821
- Author
- Igarashi T
- Niwano S
- Niwano H
- Yoshizawa T
- Nakamura H
- Fukaya H
- Fujiishi T
- Ishizue N
- Satoh A
- Kishihara J
- Murakami M
- Ako J
- Publication year
- Publication venue
- Heart and Vessels
External Links
Snippet
Abstract Dipeptidyl peptidase 4 (DPP-4) inhibitors have recently been reported to exhibit additional cardioprotective effects; however, their effect in atrial remodeling, such as in atrial fibrillation (AF), remains unclear. In this study, the effect of linagliptin on atrial electrical and …
- 206010003658 Atrial fibrillation 0 title abstract description 60
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Costantini et al. | The homeodomain transcription factor Irx5 establishes the mouse cardiac ventricular repolarization gradient | |
| Nishinarita et al. | Canagliflozin suppresses atrial remodeling in a canine atrial fibrillation model | |
| Dai et al. | Cardiac aging in mice and humans: the role of mitochondrial oxidative stress | |
| Igarashi et al. | Linagliptin prevents atrial electrical and structural remodeling in a canine model of atrial fibrillation | |
| Lim et al. | The novel adipocytokine visfatin exerts direct cardioprotective effects | |
| Li et al. | Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteins | |
| Kikuchi et al. | Targeted modification of atrial electrophysiology by homogeneous transmural atrial gene transfer | |
| Pereira et al. | Epac enhances excitation–transcription coupling in cardiac myocytes | |
| Egom et al. | Impaired sinoatrial node function and increased susceptibility to atrial fibrillation in mice lacking natriuretic peptide receptor C | |
| Whaley-Connell et al. | Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat | |
| Ford et al. | Human Electrophysiological and Pharmacological Properties of XEN-D0101: A Novel Atrial-Selective Kv1. 5/I: Kur: Inhibitor | |
| Zou et al. | dl-3-Hydroxybutyrate administration prevents myocardial damage after coronary occlusion in rat hearts | |
| Polina et al. | Loss of insulin signaling may contribute to atrial fibrillation and atrial electrical remodeling in type 1 diabetes | |
| Burashnikov et al. | Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone | |
| Burashnikov et al. | Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure | |
| Kimura et al. | Role of mineralocorticoid receptor on atrial structural remodeling and inducibility of atrial fibrillation in hypertensive rats | |
| Savi et al. | Antiarrhythmic effect of growth factor-supplemented cardiac progenitor cells in chronic infarcted heart | |
| Chang et al. | Inhibition of advanced glycation end products formation attenuates cardiac electrical and mechanical remodeling and vulnerability to tachyarrhythmias in diabetic rats | |
| Huang et al. | Glucagon-like peptide-1 regulates calcium homeostasis and electrophysiological activities of HL-1 cardiomyocytes | |
| Ferreiro et al. | Intracellular Ca2+ release underlies the development of phase 2 in mouse ventricular action potentials | |
| Fredj et al. | Altered Na+ channels promote pause-induced spontaneous diastolic activity in long QT syndrome type 3 myocytes | |
| Massare et al. | Diminished cardiac fibrosis in heart failure is associated with altered ventricular arrhythmia phenotype | |
| Guo et al. | Pinocembrin ameliorates arrhythmias in rats with chronic ischaemic heart failure | |
| Fu et al. | Mechanism of electrical remodeling of atrial myocytes and its influence on susceptibility to atrial fibrillation in diabetic rats | |
| Jeyaraj et al. | Ionic bases for electrical remodeling of the canine cardiac ventricle |